MarketMoodz
Sun Pharma to buy Organon for $11.75B in all-cash deal
Sun Pharmaceutical Industries is acquiring Organon & Co. in an all-cash deal valued at $11.75 billion, including debt, CNBC reports. The cross-border move expands Sun Pharma’s footprint and diversifies its revenue with Organon’s women’s health, biosimilars and innovative medicines lineup.
Key Takeaways
- All-cash enterprise value of $11.75 billion, or $14 per Organon share for all outstanding shares.
- Organon, spun off from Merck in 2021, focuses on women’s health and biosimilars and operates in about 140 countries with 70+ products.
- Deal would lift Sun Pharma revenue to about $12.4 billion and place it among the top 25 global pharma companies.
- Sun Pharma's Innovative Medicines segment accounted for about 20% of FY2025 sales and is expected to contribute about 27% of topline after the deal.
- Deal is subject to regulatory approvals and customary closing conditions; financing details are not disclosed and timing remains unclear.
People Involved
- Dilip ShanghviSun Pharmaceutical Industries Founder and CEO
- Carrie CoxOrganon & Co. CEO
Entities Involved
- Sun Pharmaceutical Industries Ltd.Indian pharmaceutical company; buyer in the deal
- Organon & Co.U.S.-listed company; target; biosimilars and women's health
MarketMoodz Analysis
For investors, the deal accelerates Sun Pharma's growth engine by gaining Organon’s U.S. footprint, biosimilars and women’s health portfolio, potentially lifting revenue to about $12.4 billion and boosting the Innovative Medicines share to roughly 27% of top line. The cross-border, all-cash structure also implies tighter balance-sheet discipline and wider funding considerations for Sun Pharma.
This move mirrors a broader pharma consolidation trend as companies seek scale and diversification beyond generics. Organon’s spin-off from Merck in 2021 provided a ready-made platform for growth, but regulators will scrutinize the deal and integration risk looms as Sun Pharma absorbs a U.S.-based portfolio. Watch regulatory milestones, closing timing, and how the combined company manages debt and leverage post-close.
Source: Original Article